Cargando…

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice

Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailabi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Di, Baldwin, Paige, Leal, Ana S., Carapellucci, Sarah, Sridhar, Srinivas, Liby, Karen T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735511/ https://www.ncbi.nlm.nih.gov/pubmed/31534547 http://dx.doi.org/10.7150/thno.36281

Ejemplares similares

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin, Paige, et al.
Publicado: (2018)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
por: Baldwin, Paige, et al.
Publicado: (2019)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization
por: Conceição, Carlota J. F., et al.
Publicado: (2023)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
por: Lesueur, Paul, et al.
Publicado: (2018)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
por: Ordonez, Liliana D., et al.
Publicado: (2019)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
por: Tacconi, Eliana MC, et al.
Publicado: (2019)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
por: Baldwin, Paige, et al.
Publicado: (2018)

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
por: Gruber, Joshua J., et al.
Publicado: (2022)

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
por: Attwa, Mohamed W, et al.
Publicado: (2020)

The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice
por: Reich, Lyndsey A., et al.
Publicado: (2023)

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
por: Sun, Chong-kui, et al.
Publicado: (2014)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
por: Ragupathi, Ashwin, et al.
Publicado: (2023)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
por: Leal, Ana S., et al.
Publicado: (2019)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
por: Yazinski, Stephanie A., et al.
Publicado: (2017)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
por: Litton, J. K., et al.
Publicado: (2017)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)

PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
por: Su, Cathy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o19mi61v8q1m61o8j4595s0ths